|
Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load Clinical research trials and Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load. Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load clinical trial. Human subjects frequently get the finest healthcare available for their Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load  Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
For Condition: HIV Infections
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , New York Hospital - Cornell Medical Center
Synopsis: The purpose of this study is to determine if HIV-specific canarypox vaccine and/or interleukin-2 (IL-2) will control viral load (amount of HIV in the blood) after HIV treatment is withdrawn for a certain time period.
Details: Step I: In addition to continuing HAART, patients are randomized into 1 of the following 4 arms: A: Immunization placebo; B: Immunization with the canarypox HIV-vaccine (vCP1452); C: Daily low-dose IL-2 + immunization placebo; or D: Daily low-dose IL-2 + canarypox HIV-vaccine (vCP1452). Patients on Arms A, B, C, and D receive vaccine (or vaccine placebo) injections at Weeks 0, 4, 8, and 12. Patients on Arms C and D receive IL-2 by self-injection. HAART is not provided as part of this study. Step II: Patients on all arms (A, B, C, and D) who meet inclusion criteria advance to Step II and interrupt HAART for a minimum of 12 weeks. The efficacy of these immunological therapies will be determined by monitoring the dynamics of viral rebound upon cessation of antiviral therapy. After 12 weeks of Step II, patients whose viral load remains below 30,000 copies/ml remain on Step II, off HAART, and continue weekly viral load monitoring. Patients will not terminate Step II or resume HAART unless and until their viral load increases to more than 30,000 copies/ml on 3 successive determinations, or their CD4 count decreases to less than 200 cells/mm3 or less than 50 percent of the baseline CD4+ T cell concentration on 2 successive occasions.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind
Minimum Age/Maximum Age: 19 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients may be eligible for this study if they: - Are HIV-positive. - Are more than 18 years old. - Have been receiving their current HAART (2 or more anti-HIV drugs in combination) for more than 6 consecutive months. - Have a CD4 count of 200 cells/microL or more within the 12 months prior to entering the study and 400 cells/microL or more on 2 occasions at least 2 weeks apart within 30 days of entry. - Have never had a viral load higher than 2 million molecules/ml and have had the viral load controlled with HAART to less than 50 molecules/ml on 2 occasions at least 2 weeks apart within 30 days of entry. - Have not had virologic failure on the current HAART regimen. - Have a negative urine pregnancy test within 14 days of entering the study. Exclusion Criteria Patients will not be eligible for this study if they: - Have a current AIDS-defining illness. - Have had failure of the current HAART regimen (viral load higher than 10,000 molecules/ml). - Have a history of using agents affecting the immune system. - Have active uncontrolled heart disease. - Have had IL-2 therapy within 4 weeks of entering the study. - Have received other treatment that affects the immune system within 4 weeks of entry. - Have a history of a cancer requiring chemotherapy. - Have untreated thyroid disease, within 4 weeks of entering the study. - Have uncontrolled allergic disorders or autoimmune diseases, including asthma, inflammatory bowel disease, and psoriasis. - Abuse substances that may interfere with the ability to follow study requirements. - Are allergic to eggs. - Have hepatitis B or hepatitis C. - Are pregnant or breast-feeding. - Work in close contact with canaries, such as a job at breeding farms or bird shops.
Total Enrollment: 92
Location and Contact Information:
Overall Study Official:
KendallSmith, Principal Investigator,
New York Hosp - Cornell Med Ctr *Recruiting*
New York City, New York, 10021
United States
Recruiting Ann Dunne 212-746-4435
Additional Information:
Study ID Numbers: B012; 0900-397
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00013663
Other Hiv Infections Studies:
1. A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies with Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient
2. A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 mg) or Rifabutin (300 mg) or Placebo
3. The Safety of Tenofovir Disoproxil Fumarate Taken with Other Anti-HIV Drugs to Treat HIV-Infected Patients
4. A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible
5. An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients
Related Studies:
Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
|
|
|
|
|
|
|
|
